WO1996012492A1 - Microbial synthesis of hiv protease inhibitors - Google Patents

Microbial synthesis of hiv protease inhibitors Download PDF

Info

Publication number
WO1996012492A1
WO1996012492A1 PCT/US1995/013628 US9513628W WO9612492A1 WO 1996012492 A1 WO1996012492 A1 WO 1996012492A1 US 9513628 W US9513628 W US 9513628W WO 9612492 A1 WO9612492 A1 WO 9612492A1
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
compound
aids
treatment
culture
Prior art date
Application number
PCT/US1995/013628
Other languages
French (fr)
Inventor
Ali Shafiee
Shieh-Shung T. Chen
Byron H. Arison
Randall R. Miller
George M. Garrity
Brian Heimbuch
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to CA 2203272 priority Critical patent/CA2203272A1/en
Priority to EP95937602A priority patent/EP0785786A4/en
Priority to AU39663/95A priority patent/AU702122B2/en
Priority to JP8514082A priority patent/JPH10507917A/en
Publication of WO1996012492A1 publication Critical patent/WO1996012492A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention is concerned with a novel process for synthesizing compounds that inhibit the protease encoded by human immunodeficiency virus (HIV), and in particular certain oligopeptide analogs, such as derivatives of Compound J in the Examples below. These compounds are of value in the prevention of infection by HIV, the treatment of infection by HIV and the treatment of the resulting acquired immune deficiency syndrome (AIDS). These compounds are also useful for inhibiting renin and other proteases.
  • HIV human immunodeficiency virus
  • oligopeptide analogs such as derivatives of Compound J in the Examples below.
  • AIDS acquired immune deficiency syndrome
  • HIV HIV
  • LAV low-density virus
  • HTLV-III HTLV-III
  • ARV advanced immune deficiency syndrome
  • a common feature of retrovirus replication is the extensive post-translational processing of precursor polyproteins by a viral ly encoded protease to generate mature viral proteins required for virus assembly and function. Inhibition of this processing prevents the production of normally infectious virus. For example, Kohl, N. E. ct ai, Proc. Nat'l Acacl.
  • the nucleotide sequence of HIV shows the presence of a roj gene in one open reading frame [Ratner, L. ct ai. Nature. 313, 277 ( 1985) . Amino acid sequence homology provides evidence that the go! sequence encodes reverse transcriptase, an endonuclease and an HIV protease [Toh, H. et ai, EMBO J., 4, 1267 ( 1985); Power, M. D. ct ai. /12492 PC17US95/13628
  • Applicants have identified and synthesized a variety of derivatives of Compound J, by incubating Compound J with a selected microbial system, MA7065.
  • the new compounds are active and potent inhibitors of HIV protease.
  • Biotransformation products of a fermentation with culture MA7065 are potent HIV protease inhibitors. These products are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
  • a method for synthesizing biotransformation products of the Compound J having the structure:
  • a preferred compound is compound A. Also covered are the purified biotransformation products of this method, as well as the corresponding chemical compounds.
  • Streptomyces sp. MA7065 AS2023, CRA-3-4 ATCC .
  • This culture produces analogs of Compound J, an inhibitor of HIV protease, by biotransformation. Observations of growth, general cultural characteristics and carbon source utilization were made in accordance with the methods of Shirling and Gottleib (Internal. J. System. Bacterial. 16, 313 - 340). Chemical composition of the cells was determined using the methods of Lechevalier and Lechevalier (in Actinomycete Taxonomy, A. Dietz and D. W. Thayer, Ed., Society for Industrial Microbiology, 1980).
  • Source - Culture MA7065 was isolated from a soil sample collected in a fire-break beside a fallow field that had undergone controlled burning 48h prior to sampling. The field was located in Santa Rosa Park, Guanacaste PR, Costa Rica.
  • Chemotaxonomic characteristics The peptidoglycan of MA7065 contains LL-diaminopimelic acid. Major whole cell fatty acids are listed in Table 1.
  • Micromorphology - Aerial mycelia arise from substrate mycelia in a verticilate fashion.
  • the aerial mycelium terminates in chains of spores that occur as short, loosely coiled spirals. Sporulation occurs on yeast extract malt extract agar, inorganic salts-starch agar, oatmeal, glycerol asparagine agar, Czapek's agar and tap-water agar.
  • the aerial spore mass coalesces on inorganic salts-starch agar.
  • MA7065 has a type I cejl wall. Mo ⁇ hological studies reveal that the culture produces short chains of spores on spiral sporophores, arranged in pseudoverticils which arise from the aerial mycelium. These are characteristics that are typical for some strains of Streptomyces spp. A comparison of the phenotypic data for MA7065 with that of the validly published species of Streptomyces in the taxonomic literature shows that this strain bears some resemblance to Streptomyces albo riseolus, Stmy. lydicus, Stmy. parvulus and Stmy. rochcii. Of these species, only Stmy.
  • MA7065 is a novel strain of Stmy. lydicus.
  • the preferred sources of nitrogen are yeast extract, meat extract, peptone, gluten meal, cottonseed meal, soybean meal and other vegetable meals (partially or totally defatted), casein hydrolysates, soybean hydrolysates, and yeast hydrolysates, co steep liquor, dried yeast, wheat germ, feather meal, peanut powder, distiller's solubles, etc., as well as inorganic and organic nitrogen compounds such as ammonium salts (e.g., ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea, amino acids, and the like.
  • ammonium salts e.g., ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.
  • urea amino acids, and the like.
  • the carbon and nitrogen sources need not be used in their pure form, because less pure materials which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use.
  • the medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, cobalt salts, and the like.
  • a defoaming agent such as liquid paraffin, fatty oil, plant oil, mineral oil or silicone may be added.
  • the compounds of this invention can also be obtained by synthetic organic procedures by a skilled artisan.
  • a shaking or surface culture in a flask or bottle is employed.
  • the vegetative forms of the organism for inoculation in the production tanks in order to avoid growth lag in the process of production. Accordingly, it is desirable first to produce a vegetative inoculum of the organism by inoculating a relatively small quantity of culture medium with spores or mycelia of the organism produced in a "slant" and culturing said inoculated medium, also called the "seed medium", and then to transfer the cultured vegetative inoculum aseptically to large tanks.
  • the fermentation medium, in which the inoculum is produced is generally autoclaved to sterilize the medium prior to inoculation.
  • Agitation and aeration of the culture mixture may be accomplished in a variety of ways. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermentor, by various pumping equipment or by the passage of sterile air through the medium. Aeration may be effected by passing sterile air through the fermentation mixture.
  • the fermentation is usually conducted at a temperature between about 20°C and 40°C, preferably 25-35°C, for a period of about 10 hours to 64 hours, which may be varied according to fermentation conditions and scales.
  • the production cultures are incubated for about 48 hours at 28°C on a rotary shaker operating at 220 ⁇ m, wherein the pH of the fermentation medium is maintained at 4.85 to harvest.
  • Preferred culturing/production media for carrying out the fermentation include the following media:
  • Seed medium consisted of: 0.1 % dextrose; 1 % dextrin; 0.3% beef extract; 0.5% ardamine pH; 0.5% NZ amine type E; 0.005% MgS ⁇ 4-7H2 ⁇ , and 0.037% K2HPO4 with pH adjusted to 7.1 with 0.05% CaC03.
  • Biotransformation medium contained: 2% glucose; 0.5% soya meal; 0.5% yeast extract; 0.5% NaCl; 0.98% MES with pH adjusted to 7.0. The products can be recovered from the culture medium by conventional means which are commonly used for the recovery of other known substances.
  • the substances produced are obtained by filtering or centrifuging the cultured broth, by a conventional method such as concentration under reduced pressure, lyophilization, extraction with a conventional solvent, such as methylene chloride or methanol and the like, pH adjustment, treatment with a conventional resin (e.g., anion or cation exchange resin, non-ionic adso ⁇ tion resin, etc.), treatment with a conventional adsorbent (e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), crystal ⁇ lization, recrystallization, and the like.
  • a conventional resin e.g., anion or cation exchange resin, non-ionic adso ⁇ tion resin, etc.
  • a conventional adsorbent e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.
  • the compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds.
  • the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds.
  • the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV protease, e.g., by competitive inhibition.
  • the compounds of this invention are commercial products to be sold for these pu ⁇ oses.
  • the compounds of the present invention are useful in the inhibition of HIV protease, the prevention or treatment of infection by the human immunodeficiency virus (HIV) and the treatment of consequent pathological conditions such as AIDS.
  • HIV human immunodeficiency virus
  • Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV.
  • the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
  • the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
  • a method of treating and a pharmaceutical composition for treating HIV infection and AIDS involves administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutical ly effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
  • compositions may be in the form of orally-administrable suspensions or tablets; nasal sprays; sterile injectable preparations, for example, as sterile injectable aqueous or oleagenous suspensions or suppositories.
  • these compositions When administered orally as a suspension, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweetners/flavoring agents known in the art.
  • these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art.
  • these compositions When administered by nasal aerosol or inhalation, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, abso ⁇ tion promoters to enhance bioavailability, fluorocarbons. and/or other solubilizing or dispersing agents known in the art.
  • the injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally- acceptable diluents or solvents, such as mannitol, 1 ,3-butanediol. water. Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • suitable non-toxic, parenterally- acceptable diluents or solvents such as mannitol, 1 ,3-butanediol. water.
  • Ringer's solution or isotonic sodium chloride solution or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
  • compositions When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable non- irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
  • a suitable non- irritating excipient such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
  • Dosage levels of the order of 0.02 to 5.0 or 10.0 grams- per-day are useful in the treatment or prevention of the above-indicated conditions, with oral doses two-to-five times higher.
  • infection by HIV is effectively treated by the administration of from 1.0 to 50 milligrams of the compound per kilogram of body weight from one to four times per day.
  • dosages of 100- 400 mg every six hours are administered orally to each patient.
  • the present invention is also directed to combinations of the HIV protease inhibitory compounds with one or more agents useful in the treatment of AIDS.
  • the compounds of this invention may be effectively administered, whether at periods of pre- exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, anti-infectives, or vaccines known to those of ordinary skill in the art.
  • Ganciclovir (Palo Alto, CA) peripheral CMV retinitis
  • Virazole Viratek/ICN asymptomatic HIV Ribavirin (Costa Mesa, CA) positive, LAS, ARC
  • Methionine- TNI Pharmaceutical AIDS, ARC Enkephalin (Chicago, IL)
  • Granulocyte Amgen AIDS in combination Colony Stimulating (Thousand Oaks, CA) w/AZT Factor
  • TNF S. San Francisco, w/gamma Interferon CA
  • Isethionate (IM & IV) (Rosemont, IL)
  • Compound B is 6-chloro-4-(S)-cyclopropyl-3,4-dihydro-4-((2- pyridyl)ethynyl)quinazolin-2( 1 H)-one;
  • Compound C is(-) 6-chloro-4(S)-trifluoromethyl- l ,2-dihydro-4(H)-3, l - benzoxazin-2-one; nevirapine is 1 1 -cyclopropy 1-5, 1 1 -dihydro-4-methy 1- 6 /-dipyrido[3,2- ?:2',3'- ⁇ ?][ l ,4]diazepin-6-one.
  • Compounds B and C are synthesized by the methods of EP 0,569,083, herein inco ⁇ orated by reference for this pu ⁇ ose. Nevirapine is synthesized by Klunder, J. M. et ai, J. Med. Chem.
  • Preferred combinations are simultaneous or alternating treatments of an inhibitor of HIV protease and a non-nucleoside inhibitor of HIV reverse transcriptase.
  • An optional third component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, ddC or ddl.
  • a preferred inhibitor of HIV protease is Compound A.
  • Preferred non-nucleoside inhibitors of HIV reverse transcriptase include Compound B, Compound C or nevirapine. These combinations may have synergistic effects on limiting the spread of HIV. Preferred combinations include the following ( 1 ) Compound A, with a preferred non-nucleoside inhibitor of HIV reverse transcriptase, and, optionally, AZT or ddl or ddC; (2) Compound A, and any of AZT or ddl or ddC.
  • the reaction was quenched with 160 ⁇ l of 5% phosphoric acid.
  • Products of the reaction were separated by HPLC (VYDAC wide pore 5 cm C- 18 reverse phase, acetonitrile gradient, 0.1 % phosphoric acid).
  • the extent of inhibition of the reaction was determined as IC50 from the peak heights of the products.
  • Inhibition of the spread of HIV in cell culture was measured according to Nunberg, J. H. et al., J. Virol. 65, 4887 (1991 ).
  • MT-4 T-lymphoid cells were infected with HIV- 1 (wild- type, unless otherwise indicated) by using a predetermined inoculum, and cultures were incubated for 24 h. At this time, ⁇ 1 % of the cells were positive by indirect immunofluorescence. Cells were then extensively washed and distributed into 96-well culture dishes. Serial twofold dilutions of inhibitor were added to the wells, and cultures were continued for 3 additional days. At 4 days postinfection, 100% of the cells in control cultures were infected. HIV-1 p24 accumulation was directly correlated with virus spread.
  • the cell culture inhibitory concentration was defined as the inhibitor concentration in nanomoles/liter which reduced the spread of infection by at least 95%, or CIC95-
  • MT cells were infected at Day 0 at a concentration of 250,000 per ml with a 1 : 1000 dilution of HIV-1 strain Illb stock (final 125 pg p24/ml; sufficient to yield ⁇ 1 % infected cells on day 1 and 25- 100% on day 4).
  • Cells were infected and grown in the following medium: RPMI 1640 (Whittaker BioProducts), 10% inactivated fetal bovine serum, 4 mM glutamine (Gibco Labs) and 1 : 100 Penicillin- Streptomycin (Gibco Labs).
  • the mixture was incubated overnight at 37°C in 5% C02 atmosphere.
  • the settled cells are resuspended and 125 ⁇ l harvested into a separate microtiter plate.
  • the supernatant is assayed for HIV p24 antigen.
  • the concentration of HIV p24 antigen is measured by an enzyme immunoassay, described as follows. Aliquots of p24 antigen to be measured are added to microwells coated with a monoclonal antibody specific for HIV core antigen. The microwells are washed at this point, and at other appropriate steps that follow. Biotinylated HIV-specific antibody is then added, followed by conjugated streptavidin- horseradish peroxidase. A color reaction occurs from the added hydrogen peroxide and tetramethylbenzidine substrate. Color intensity is proportional to the concentration of HIV p24 antigen.
  • fractional inhibitory concentration ratios are calculated according to Elion, et ai, J. Biol. Chem., 208, All ( 1954).
  • the minimum sum of FICS which is the maximum synergy, is determined for various pairwise combinations. The smaller the number, the greater the synergy.
  • A. Culture Preparation Culture MA7065 was grown in seed and biotransformation media, respectively.
  • Seed medium (KE medium) consisted of: 0.1 % dextrose; 1 % dextrin; 0.3% beef extract; 0.5% ardamine pH; 0.5% NZ amine type E; 0.005% MgS ⁇ 4 « 7H2 ⁇ , and 0.037% K2HPO4 with pH adjusted to 7.1 with 0.05% CaC03.
  • Biotransformation medium contained: 2% glucose; 0.5% soya meal; 0.5% yeast extract; 0.5% NaCl: 0.98% MES with pH adjusted to 7.0.
  • MA7065 was grown in KE seed medium. After overnight incubation at 27°C with gyratory shake (220 ⁇ m) two milliliters of each culture was transferred into 250 ml baffled flasks containing 50 ml of soy-glucose bioconversion medium. At zero time, 5 mg of
  • HIV-protease inhibitor Compound J
  • the supernatant was recovered and applied on the top of an activated column containing 14% octadecyl support.
  • the column was washed with water and then eluted with a gradient of an aqueous methanol from 20 to 80%.
  • Each eluted fraction was examined by HPLC on an analytical column.
  • This column was developed with a gradient solvent system consisting of reservoir A and B.
  • Reservoir A contained 10% ammonium acetate : 0.1 % formic acid and reservoir B contained 67% acetonitrile : 33% methanol : 0.1 % formic acid.
  • the gradient was run from 30 to 85% solvent B in 30 min.
  • Mass spectra and daughter ion spectra were obtained by LC/MS/MS on a mass spectrometer using the ionspray interface. Samples were analyzed by direct injection in a mobile phase that consisted of 50% CH3CN/50% 10 mM NH4 ⁇ Ac/0.1 % TFA. Positive ion detection was used.
  • the dilution of the test compound was based on nominal weight. In other cases, especially when the weight was less than 250 ⁇ g, the concentration was checked by HPLC using J as standard.
  • the reaction was treated with pyridinium -toluene- sulfonate (241 g, 0.96 mol, 0.16 equiv.) and stirred for 10 minutes (the pH of the mixture after diluting 1 mL sample with an equal volume of water is between 4.3-4.6). Then, 2-methoxypropene ( 1.27 L, 13.24 mol, 2.2 equiv.) was added and reaction was heated to 38-40°C for 2 h. The reaction mixture was cooled to 20°C and partitioned with ethyl acetate ( 12 L) and 5% aqueous NaHC ⁇ 3 (10 L). The mixture was agitated and the layers were separated.
  • the ethyl acetate extract was washed with 5% aqueous NaHC03 (10 L) and water (4 L).
  • the ethyl acetate extract was dried by atmospheric distillation and solvent switched to cyclohexane (total volume of ⁇ 30L).
  • the hot cyclohexane solution was allowed to slowly cool to 25°C to crystallize the product.
  • the resulting slurry was further cooled to 10°C and aged for 1 h.
  • the product was isolated by filtration and the wet cake was washed with cold ( 10°C) cyclohexane (2 X 800 mL).
  • lithium hexamethyldisilazide LiN[(CH3)3Si]2)(2.6 L, 1.38 M, 1.15 equiv.
  • the reaction mixture was stirred at -45 to -40°C for 1 h and then allowed to warm to -25°C over 1 h.
  • the mixture is stirred between -25 to -22°C for 4 h (or until the starting acetonide is 3.0 area %).
  • the mixture was partitioned with ethyl acetate (40 L) and water (3 L). The mixture was agitated and the layers were separated.
  • the HPLC assay yield of 6 in ethyl acetate was 86.5%.
  • the penultimate compound 6 in DMF was directly used in the next step without further purification.
  • the carboxylic acid 8 was suspended in 27 L of EtOAc and 120 mL of DMF in a 72 L 3-neck flask with mechanical stirring under N2 and the suspension was cooled to 2°C. The oxalyl chloride was added, maintaining the temperature between 5 and 8°C.
  • the assay for completion of the acid chloride formation is important because incomplete reaction leads to formation of a bis-tert- butyl oxamide impurity.
  • the reaction mixture was aged at 5°C for 1 h.
  • the resulting slurry was cooled to 0°C and the tert-butylamine was added at such a rate as to keep the internal temperature below 20°C.
  • the mixture was aged at 18°C for an additional 30 min.
  • the precipitated ammonium salts were removed by filtration.
  • the filter cake was washed with 12 L of EtOAc.
  • the combined organic phases were washed with 6 L of a 3% NaHC ⁇ 3 and 2 X 2 L of saturated aq. NaCl.
  • the organic phase was treated with 200 g of Darco G60 carbon and filtered through Solka Flok and the cake was washed with 4 L of EtOAc.
  • the EtOAc solution of 9 was concentrated at 10 mbar to 25% of the original volume. 30 L of 1-propanol were added, and the distillation was continued until a final volume of 20 L was reached.
  • the pyrazine-2-tert-butylcarboxamide 9/1 -propanol solution was placed into the 5 gal autoclave.
  • the catalyst was added and the mixture was hydrogenated at 65°C at 40 psi (3 arm) of H2.
  • reaction was monitored by GC: 30 m Megabore column, from 100°C to 160°C at 10°C/min, hold 5 min, then at
  • HPLC 25 cm Dupont Zorbax RXC8 column with 1.5 mL/min flow and detection at 210 nm, isocratic (98/2) CH3CN/O.I % aqueous H3PO4.
  • CH3CN/I -propanol ratio by lH NMR integration showed that the CH3CN/l -propanol/H2 ⁇ ratio was 26/8/1.6.
  • the concentration in the solution was 72.2 g/ L.
  • the (S)-lO-camphorsu.fonic acid was charged over 30 min in 4 portions at 20°C. The temperature rose to 40°C after the CSA was added. After a few minutes a thick white precipitate formed. The white slurry was heated to 76°C to dissolve all the solids, the slightly brown solution was then allowed to cool to 21 °C over 8 h.
  • the ee of the material was 95% according to the following chiral HPLC assay: an aliquot of 11 (33 mg) was suspended in 4 mL of EtOH and 1 mL of Et3N. Boc2 ⁇ ( 1 1 mg) was added and the reaction mixture was allowed to age for 1 h. The solvent was completely removed in vacua, and the residue was dissolved in ca. 1 mL of EtOAc and filtered through a Pasteur pipet with Si ⁇ 2, using EtOAc as eluent. The evaporated product fractions were redissolved in hexanes at ca. 1 mg/mL.
  • the chiral assay was carried out using the same system as in the previous step.
  • the solution was then concentrated to ca. 10 L at an internal temperature of ⁇ 20°C in a batch-type concentrator under 10 mbar vacuum.
  • the solvent switch was completed by slowly bleeding in 20 L of EtOAc and reconcentrating to ca 10 L.
  • the reaction mixture was washed into an extractor with 60 L of EtOAc.
  • the organic phase was washed with 16 L of 5% aqueous Na2C ⁇ 3 solution, 2 X 10 L Di water and 2 X 6 L of saturated aqueous sodium chloride.
  • the combined aqueous washes were back extracted with 20 L of EtOAc and the organic phase was washed with 2 X 3 L water and 2 X 4 L of saturated aqueous sodium chloride.
  • the combined EtOAc extracts were concentrated under 10 mbar vacuum with an internal temperature of ⁇ 20°C in a 100 L batch-type concentrator to ca. 8 L.
  • the solvent switch to cyclohexane was achieved by slowly bleeding in ca. 20 L of cyclohexane, and reconcentrating to ca. 8 L.
  • To the slurry was added 5 L of cyclohexane and 280 mL of EtOAc and the mixture was heated to reflux, when everything went into solution.
  • the solution was cooled and seed ( 10 g) was added at 58°C.
  • the slurry was cooled to 22°C in 4 h and the product was isolated by filtration after a 1 h age at 22°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Biotransformation products of a fermentation with culture MA7065 are potent HIV protease inhibitors. These products are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

Description

TITLE OF THE INVENTION
MICROBIAL SYNTHESIS OF HIV PROTEASE INHIBITORS
BACKGROUND OF THE INVENTION The present application is related to Merck 19276, 18996 and 18996IA.
The present invention is concerned with a novel process for synthesizing compounds that inhibit the protease encoded by human immunodeficiency virus (HIV), and in particular certain oligopeptide analogs, such as derivatives of Compound J in the Examples below. These compounds are of value in the prevention of infection by HIV, the treatment of infection by HIV and the treatment of the resulting acquired immune deficiency syndrome (AIDS). These compounds are also useful for inhibiting renin and other proteases. A retrovirus designated human immunodeficiency virus
(HIV) is the etiological agent of the complex disease that includes progressive destruction of the immune system (acquired immune deficiency syndrome; AIDS) and degeneration of the central and peripheral nervous system. This virus was previously known as LAV, HTLV-III, or ARV. A common feature of retrovirus replication is the extensive post-translational processing of precursor polyproteins by a viral ly encoded protease to generate mature viral proteins required for virus assembly and function. Inhibition of this processing prevents the production of normally infectious virus. For example, Kohl, N. E. ct ai, Proc. Nat'l Acacl. Sci., H5, 4686 (1988) demonstrated that genetic inactivation of the HIV encoded protease resulted in the production of immature, non-infectious virus particles. These results indicate that inhibition of the HIV protease represents a viable method for the treatment of AIDS and the prevention or treatment of infection by HIV. The nucleotide sequence of HIV shows the presence of a roj gene in one open reading frame [Ratner, L. ct ai. Nature. 313, 277 ( 1985) . Amino acid sequence homology provides evidence that the go! sequence encodes reverse transcriptase, an endonuclease and an HIV protease [Toh, H. et ai, EMBO J., 4, 1267 ( 1985); Power, M. D. ct ai. /12492 PC17US95/13628
- 2
Science, 231 , 1567 ( 1986); Pearl, L. H. et ai, Nature, 329, 351 ( 1987)]. Compounds, including certain oligopeptide analogs that can be made from the novel processes of this invention are inhibitors of HIV protease. See EPO 541 , 168, which published on May 12, 1993. See also, for example, Compound J therein.
Previously, the synthesis of Compound J and related compounds was accomplished via a 12-step procedure. This procedure is described in EPO 541 , 168. The extreme length of this route (12 steps), renders this process time consuming and labor intensive, and it requires the use of many presently expensive reagents and a presently expensive starting material. A route requiring fewer reaction steps and reagents would provide desirable economical and time-saving benefits.
Applicants have identified and synthesized a variety of derivatives of Compound J, by incubating Compound J with a selected microbial system, MA7065. The new compounds are active and potent inhibitors of HIV protease.
SUMMARY OF THE INVENTION
Biotransformation products of a fermentation with culture MA7065 are potent HIV protease inhibitors. These products are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
DETAILED DESCRIPTION OF THE INVENTION
A method is disclosed for synthesizing biotransformation products of the Compound J, having the structure:
Figure imgf000005_0001
or salt or hydrate thereof, comprising the steps of
(a) providing a culture of MA7065;
(b) incubating said culture with Compound J;
(c) isolating biotransformation products comprising:
Figure imgf000005_0002
Compound A
Compound C1
Figure imgf000006_0001
Compound C2
Figure imgf000006_0002
Compound D
Figure imgf000006_0003
Compound E
or salt or hydrate thereof. A preferred compound is compound A. Also covered are the purified biotransformation products of this method, as well as the corresponding chemical compounds. ATCC Deposit
Before the U.S. filing date of the present application, a sample of the microorganism (Merck Culture Collection MA 7065) was deposited at the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852. The culture access designation is . This deposit will be maintained in the ATCC for at least 30 years and will be made available to the public upon the grant of a patent disclosing it. It should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by government action.
General Characteristics of ATCC
The physical characteristics and taxonomy, including moφhological, cultural, biological and physiological characteristics are briefly described hereinbelow.
On the basis of the taxonomic analysis performed thus far, the culture has been assigned to the order Streptomyces.
The following is a general description of Streptomyces sp. MA7065 (AS2023, CRA-3-4 ATCC ). This culture produces analogs of Compound J, an inhibitor of HIV protease, by biotransformation. Observations of growth, general cultural characteristics and carbon source utilization were made in accordance with the methods of Shirling and Gottleib (Internal. J. System. Bacterial. 16, 313 - 340). Chemical composition of the cells was determined using the methods of Lechevalier and Lechevalier (in Actinomycete Taxonomy, A. Dietz and D. W. Thayer, Ed., Society for Industrial Microbiology, 1980). Whole cell fatty acids were derivatized and analyzed as methyl esters (FAMEs) by gas chromatography by the procedure of Miller and Berger using a MIDI Microbial Identification System (Microbial Identification Systems. Newark, Delaware). Coloration of the culture was determined by comparison with color standards contained in the Inter-Society Color Council -National Bureau of Standards Centroid Color Charts (US Dept. of Commerce National Bureau of Standards supplement to NBS Circular 553, 1985).
Source - Culture MA7065 was isolated from a soil sample collected in a fire-break beside a fallow field that had undergone controlled burning 48h prior to sampling. The field was located in Santa Rosa Park, Guanacaste PR, Costa Rica.
Chemotaxonomic characteristics - The peptidoglycan of MA7065 contains LL-diaminopimelic acid. Major whole cell fatty acids are listed in Table 1.
TABLE 1
Major Whole Cell Fatty
Acids Found in MA7065
Fatty acid % age
14:0 iso 6.04
15:0 iso 10.56
15:0 anteiso 9.61
15:0 2.23
16:0 iso H 7.77
16:0 iso 28.50
15:0 iso 2 OH 4.81
15:0 anteiso 2 OH 3.55
16:0 3.55
17:0 anteiso C 4.01
17:0 iso 4.09
17:0 anteiso 4.71
16:0 iso 20H 3.31
18: 1 iso H 1.60
General growth characteristics - Good to excellent growth was observed on yeast-extract malt-extract agar, glycerol-asparagine, inorganic salts-starch agar, Czapek's agar, Sabouraud Maltose agar, oatmeal agar and trypticase soy broth agar. Fair growth was observed on tap water agar. Growth occurred at 27° and 37 °C. See Table 2.
TABLE 2
Cultural Characteristics of Actinomycete sp. MA7065
Medium Amount of Aerial Soluble Substrate growth mycelium pigments mycelium
Yeast Extract Excellent Light gray (264 l.Gy) None Dark yellow Malt Extract Short, loosely coiled brown (75 d spirals on y.Br) pseudoverticils
Glucose Good Light gray (264 l.Gy) None Dark orange Aspargine Short, loosely coiled yellow (72d. spirals on OY) pseudoverticils
Inorganic Good Black (267 Black) None Yellowish Salts-Starch Short, loosely coiled white (92 y. spirals on pseudo¬ White) verticils, extensive coalescence
Oatmeal Excellent Light gray (264 l.Gy) None Grayish yellow Short, loosely coiled (90 gy.Y) spirals on pseudoverticils
Czapek Good White (263 White) None Grayish yellow Flexous filaments, (90 gy.Y) few spirals
Tap Water Fair Light gray (264 l.Gy) None Colorless Short, loosely coiled spirals on pseudoverticils. highly fragmented Peptone Iron H2S negative, Melanin neεative Colony morphology - (On yeast-malt agar at 2 Id) Substrate mycelium is a dark yellow brown. Aerial spore mass is abundant, cottony and yellowish gray in color. Colonies are opaque, raised, with an entire edge and matte surface. The colonies are rubbery in texture.
Micromorphology - Aerial mycelia (0.57 μm) arise from substrate mycelia in a verticilate fashion. In mature cultures (7 - 28d p.i.) the aerial mycelium terminates in chains of spores that occur as short, loosely coiled spirals. Sporulation occurs on yeast extract malt extract agar, inorganic salts-starch agar, oatmeal, glycerol asparagine agar, Czapek's agar and tap-water agar. The aerial spore mass coalesces on inorganic salts-starch agar.
Miscellaneous physiological reactions - Culture does not produce H2S in peptone-iron agar. Melanoid pigments were not formed in either peptone-iron agar or tryptone-yeast extract broth. Starch was weakly hydrolyzed. Carbon source utilization pattern is as follows: good utilization of D-arabinose, L-arabinose, D-fructose, α-D-glucose, inositol, -D-lactose, β-D-lactose, D-maltose, D-mannitol, D-mannose, L-rhamnose, and sucrose; moderate utilization of D-raffinose and D-xylose. See Table 3.
TABLE 3
Carbon Source Utilization Pattern of Strains MA7065
Carbon source Growth
D-arabinose 2
L-arabinose 2
D-fructose 3 inositol 3 α-D-lactose 3 β-D-lactose 3
D-maltose 3
D-mannitol 3
D-mannose 3
D-raffinose 3
L-rhamnose 2 sucrose 3
D-xylose 2 α-D-glucose (control) 3
3=good utilization, 2= moderate utilization, l=poor uti ization,
0=no utilization
Diagnosis - Cell wall analysis reveals that MA7065 has a type I cejl wall. Moφhological studies reveal that the culture produces short chains of spores on spiral sporophores, arranged in pseudoverticils which arise from the aerial mycelium. These are characteristics that are typical for some strains of Streptomyces spp. A comparison of the phenotypic data for MA7065 with that of the validly published species of Streptomyces in the taxonomic literature shows that this strain bears some resemblance to Streptomyces albo riseolus, Stmy. lydicus, Stmy. parvulus and Stmy. rochcii. Of these species, only Stmy. lydicus has been reported to exhibit coalescence of the aerial spore mass. However, the sporophores of Stmy. lydicus are not arranged in pseudoverticles. Comparison of the fatty acid profile of MA7065 against the MIDI actinomycete library (Version 3.7) showed a distant match to Stmy. lydicus.
A cluster analysis was done by furthest neighbor analysis using Euclidean distance as the metric. The results of this analysis showed MA7065 to be more similar to Stmy. lydicus than the other reference strains. These findings are consistent with moφhological and physiological data. Based upon these findings, MA7065 is a novel strain of Stmy. lydicus. The preferred sources of nitrogen are yeast extract, meat extract, peptone, gluten meal, cottonseed meal, soybean meal and other vegetable meals (partially or totally defatted), casein hydrolysates, soybean hydrolysates, and yeast hydrolysates, co steep liquor, dried yeast, wheat germ, feather meal, peanut powder, distiller's solubles, etc., as well as inorganic and organic nitrogen compounds such as ammonium salts (e.g., ammonium nitrate, ammonium sulfate, ammonium phosphate, etc.), urea, amino acids, and the like.
The carbon and nitrogen sources, though advantageously employed in combination, need not be used in their pure form, because less pure materials which contain traces of growth factors and considerable quantities of mineral nutrients, are also suitable for use. When desired, there may be added to the medium mineral salts such as sodium or calcium carbonate, sodium or potassium phosphate, sodium or potassium chloride, sodium or potassium iodide, magnesium salts, copper salts, cobalt salts, and the like. If necessary, especially when the culture medium foams seriously, a defoaming agent, such as liquid paraffin, fatty oil, plant oil, mineral oil or silicone may be added. The compounds of this invention can also be obtained by synthetic organic procedures by a skilled artisan.
As to the conditions for the production of MA7065 in massive amounts, submerged aerobic cultural conditions are preferred. For the production in small amounts, a shaking or surface culture in a flask or bottle is employed. Furthermore, when the growth is carried out in large tanks, it is preferable to use the vegetative forms of the organism for inoculation in the production tanks in order to avoid growth lag in the process of production. Accordingly, it is desirable first to produce a vegetative inoculum of the organism by inoculating a relatively small quantity of culture medium with spores or mycelia of the organism produced in a "slant" and culturing said inoculated medium, also called the "seed medium", and then to transfer the cultured vegetative inoculum aseptically to large tanks. The fermentation medium, in which the inoculum is produced, is generally autoclaved to sterilize the medium prior to inoculation.
Agitation and aeration of the culture mixture may be accomplished in a variety of ways. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the fermentor, by various pumping equipment or by the passage of sterile air through the medium. Aeration may be effected by passing sterile air through the fermentation mixture.
The fermentation is usually conducted at a temperature between about 20°C and 40°C, preferably 25-35°C, for a period of about 10 hours to 64 hours, which may be varied according to fermentation conditions and scales. Preferably, the production cultures are incubated for about 48 hours at 28°C on a rotary shaker operating at 220 φm, wherein the pH of the fermentation medium is maintained at 4.85 to harvest.
Preferred culturing/production media for carrying out the fermentation include the following media:
Seed medium (KE medium) consisted of: 0.1 % dextrose; 1 % dextrin; 0.3% beef extract; 0.5% ardamine pH; 0.5% NZ amine type E; 0.005% MgSθ4-7H2θ, and 0.037% K2HPO4 with pH adjusted to 7.1 with 0.05% CaC03. Biotransformation medium (soy-glucose) contained: 2% glucose; 0.5% soya meal; 0.5% yeast extract; 0.5% NaCl; 0.98% MES with pH adjusted to 7.0. The products can be recovered from the culture medium by conventional means which are commonly used for the recovery of other known substances. The substances produced are obtained by filtering or centrifuging the cultured broth, by a conventional method such as concentration under reduced pressure, lyophilization, extraction with a conventional solvent, such as methylene chloride or methanol and the like, pH adjustment, treatment with a conventional resin (e.g., anion or cation exchange resin, non-ionic adsoφtion resin, etc.), treatment with a conventional adsorbent (e.g., activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), crystal¬ lization, recrystallization, and the like.
The compounds of this invention are useful in the preparation and execution of screening assays for antiviral compounds. For example, the compounds of this invention are useful for isolating enzyme mutants, which are excellent screening tools for more powerful antiviral compounds. Furthermore, the compounds of this invention are useful in establishing or determining the binding site of other antivirals to HIV protease, e.g., by competitive inhibition. Thus the compounds of this invention are commercial products to be sold for these puφoses. The compounds of the present invention are useful in the inhibition of HIV protease, the prevention or treatment of infection by the human immunodeficiency virus (HIV) and the treatment of consequent pathological conditions such as AIDS. Treating AIDS or preventing or treating infection by HIV is defined as including, but not limited to, treating a wide range of states of HIV infection: AIDS, ARC (AIDS related complex), both symptomatic and asymptomatic, and actual or potential exposure to HIV. For example, the compounds of this invention are useful in treating infection by HIV after suspected past exposure to HIV by, e.g., blood transfusion, organ transplant, exchange of body fluids, bites, accidental needle stick, or exposure to patient blood during surgery.
For these puφoses, the compounds of the present invention may be administered orally, parenterally (including subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques), by inhalation spray, or rectally, in dosage unit formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles.
Thus, in accordance with the present invention there is further provided a method of treating and a pharmaceutical composition for treating HIV infection and AIDS. The treatment involves administering to a patient in need of such treatment a pharmaceutical composition comprising a pharmaceutical carrier and a therapeutical ly effective amount of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
These pharmaceutical compositions may be in the form of orally-administrable suspensions or tablets; nasal sprays; sterile injectable preparations, for example, as sterile injectable aqueous or oleagenous suspensions or suppositories. When administered orally as a suspension, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may contain microcrystalline cellulose for imparting bulk, alginic acid or sodium alginate as a suspending agent, methylcellulose as a viscosity enhancer, and sweetners/flavoring agents known in the art. As immediate release tablets, these compositions may contain microcrystalline cellulose, dicalcium phosphate, starch, magnesium stearate and lactose and/or other excipients, binders, extenders, disintegrants, diluents and lubricants known in the art. When administered by nasal aerosol or inhalation, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absoφtion promoters to enhance bioavailability, fluorocarbons. and/or other solubilizing or dispersing agents known in the art.
The injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally- acceptable diluents or solvents, such as mannitol, 1 ,3-butanediol. water. Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid.
When rectally administered in the form of suppositories, these compositions may be prepared by mixing the drug with a suitable non- irritating excipient, such as cocoa butter, synthetic glyceride esters or polyethylene glycols, which are solid at ordinary temperatures, but liquidify and/or dissolve in the rectal cavity to release the drug.
Dosage levels of the order of 0.02 to 5.0 or 10.0 grams- per-day are useful in the treatment or prevention of the above-indicated conditions, with oral doses two-to-five times higher. For example, infection by HIV is effectively treated by the administration of from 1.0 to 50 milligrams of the compound per kilogram of body weight from one to four times per day. In one preferred regimen, dosages of 100- 400 mg every six hours are administered orally to each patient. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
The present invention is also directed to combinations of the HIV protease inhibitory compounds with one or more agents useful in the treatment of AIDS. For example, the compounds of this invention may be effectively administered, whether at periods of pre- exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, anti-infectives, or vaccines known to those of ordinary skill in the art. TABLE C
ANTIVIRALS
Drug Name Manufacturer Indication
AL-721 Ethigen ARC, PGL
(Los Angeles, CA) HIV positive, AIDS
Recombinant Human Triton Biosciences AIDS, Kaposi's lnterferon Beta (Almeda, CA) sarcoma, ARC
Acemannan Carrington Labs ARC (Irving, TX) (See also immunomodulators)
Cytovene Syntex sight threatening CMV
Ganciclovir (Palo Alto, CA) peripheral CMV retinitis
d4T Bristol-Myers AIDS, ARC
Didehydrodeoxy- (New York, NY) thymidine
ddl Bristol-Myers AIDS, ARC Dideoxyinosine (New York, NY)
EL10 Elan Coφ, PLC HIV infection (Gainesville, GA) (See also immunomodulators) Drug Name Manufacturer Indication
Trisodium Astra Pharm. CMV retinitis, HIV Phosphonoformate Products, Inc infection, other CMV
(Westborough, MA) infections
Dideoxycytidine; Hoffman-La Roche AIDS, ARC ddC (Nutley, NJ)
Novapren Novaferon Labs, Inc. HIV inhibitor (Akron, OH) Diapren, Inc. (Roseville, MN, marketer)
Peptide T Peninsula Labs AIDS
Octapeptide (Belmont, CA)
Sequence
Zidovudine; AZT Burroughs Wellcome AIDS, adv, ARC AIDS, adv, ARC (Rsch. Triangle Park, pediatric AIDS, NC) Kaposi's sarcoma, asymptomatic HIV infection, less severe HIV disease, neurological involvement, in combination with other therapies.
Ansamycin LM 427 Adria Laboratories ARC (Dublin, OH) Erbamont (Stamford, CT) Drug Name Manufacturer Indication
Dextran Sulfate Ueno Fine Chem. AIDS, ARC, HIV Ind. Ltd. positive asymptomatic (Osaka, Japan)
Virazole Viratek/ICN asymptomatic HIV Ribavirin (Costa Mesa, CA) positive, LAS, ARC
Alpha Interferon Burroughs Wellcome Kaposi's sarcoma, (Rsch. Triangle HIV in combination
Park, NC) w/Retrovir
Acyclovir Burroughs Wellcome AIDS, ARC, asymptomatic HIV positive, in combination with AZT.
Antibody which Advanced Biotherapy AIDS, ARC neutralizes pH Concepts labile alpha aberrant (Rockville, MD) Interferon in an immuno-adsoφtion column
B Merck AIDS, ARC, (Rahway, NJ) asymptomatic HIV positive, also in combination with AZT. Drue Name Manufacturer Indication
C Merck AIDS, ARC,
(Rahway, NJ) asymptomatic HIV positive, also in combination with AZT.
Nevirapine Boehringer AIDS, ARC,
Ingelheim asymptomatic HIV positive, also in combination with AZT.
IMMUNO-MODULATORS
Drug Name Manufacturer Indication
AS-101 Wyeth-Ayerst Labs. AIDS (Philadelphia, PA)
Bropirimine Upjohn advanced AIDS (Kalamazoo, MI)
Acemannan Carrington Labs, Inc. AIDS, ARC (See also (Irving, TX) anti-virals)
CL246,738 American Cyanamid AIDS, Kaposi's (Pearl River, NY) sarcoma Lederle Labs (Wayne, NJ)
EL10 Elan Coφ, PLC HIV infection (Gainesville, GA) (See also anti¬ virals)
Gamma Interferon Genentech ARC, in combination
(S. San Francisco, w/TNF (tumor
CA) necrosis factor) Drug Name Manufacturer Indication
Granulocyte Genetics Institute AIDS
Macrophage Colony (Cambridge, MA)
Stimulating Sandoz
Factor (East Hanover, NJ)
Granulocyte Hoeschst-Roussel AIDS
Macrophage Colony (Somerville, NJ)
Stimulating Immunex
Factor (Seattle, WA)
Granulocyte Schering-Plough AIDS
Macrophage Colony (Madison, NJ)
Stimulating Factor AIDS, in combination w/AZT
HIV Core Particle Rorer seropositive HIV
Immunostimulant (Ft. Washington, PA)
IL-2 Cetus AIDS, in combination
Interleukin-2 (Emeryville, CA) w/AZT
IL-2 Hoffman-La Roche AIDS, ARC, HIV, in
Interleukin-2 (Nutley, NJ) combination w/AZT Immunex
Immune Globulin Cutter Biological pediatric AIDS, in
Intravenous (Berkeley, CA) combination w/AZT
(human) Drug Name Manufacturer Indication
IMREG-1 Imreg AIDS, Kaposi's
(New Orleans, LA) sarcoma, ARC, PGL
IMREG-2 Imreg AIDS, Kaposi's
(New Orleans, LA) sarcoma, ARC, PGL
Imuthiol Diethyl Merieux Institute AIDS, ARC Dithio Carbamate (Miami, FL)
Alpha-2 Schering Plough Kaposi's sarcoma Interferon (Madison, NJ) w/AZT: AIDS
Methionine- TNI Pharmaceutical AIDS, ARC Enkephalin (Chicago, IL)
MTP-PE Ciba-Geigy Coφ. Kaposi's sarcoma
Muramyl- (Summit, NJ)
Tripeptide
Granulocyte Amgen AIDS, in combination Colony Stimulating (Thousand Oaks, CA) w/AZT Factor
rCD4 Genentech AIDS, ARC
Recombinant (S. San Francisco, Soluble Human CD4 CA)
rCD4-IgG AIDS, ARC hybrids Drue Name Manufacturer Indication
Recombinant Biogen AIDS, ARC
Soluble Human CD4 (Cambridge, MA)
Interferon Hoffman-La Roche Kaposi's sarcoma
Alfa 2a (Nutley, NJ) - AIDS, ARC, in combination w/AZT
SK&F106528 Smith, Kline & HIV infection
Soluble T4 French Laboratories (Philadelphia, PA)
Thymopentin Immunobiology HIV infection Research Institute (Annandale, NJ)
Tumor Necrosis Genentech ARC, in combination
Factor; TNF (S. San Francisco, w/gamma Interferon CA)
ANTI-INFECTIVES
Drue Name Manufacturer Indication
Clindamycin with Upjohn PCP
Primaquine (Kalamazoo, MI)
Fluconazole Pfizer cryptococcal
(New York, NY) meningitis, candidiasis 96/12492 PC17US95/13628
23
Drug Name Manufacturer Indication
Pastille Squibb Coφ. prevention of
Ny statin Pastille (Princeton, NJ) oral candidiasis
Ornidyl Merrell Dow PCP Eflornithine (Cincinnati, OH)
Pentamidine LyphoMed PCP treatment
Isethionate (IM & IV) (Rosemont, IL)
Trimethoprim antibacterial
Trimethoprim/sulfa antibacterial
Piritrexim Burroughs Wellcome PCP treatment (Rsch. Triangle Park, NC)
Pentamidine Fisons Coφoration PCP prophylaxis isethionate for (Bedford, MA) inhalation
Spiramycin Rhone-Poulenc cryptosporidial Pharmaceuticals diarrhea (Princeton, NJ)
Intraconazole- Janssen Pharm. histoplasmosis; R5121 1 (Piscataway, NJ) cryptococcal meningitis
Trimetrexate Warner-Lambert PCP OTHER
Dru Name Manufacturer Indication
Recombinant Human Ortho Pharm. Coφ. severe anemia Erythropoietin (Raritan, NJ) assoc. with AZT therapy
Megestrol Acetate Bristol-Myers treatment of (New York, NY) anorexia assoc. w/AIDS
Total Enteral Norwich Eaton diarrhea and Nutrition Pharmaceuticals malabsoφtion
(Norwich, NY) related to AIDS
It will be understood that the scope of combinations of the compounds of this invention with AIDS antivirals, immunomodulators, anti-infectives or vaccines is not limited to the list in the above Table, but includes in principle any combination with any pharmaceutical composition useful for the treatment of AIDS.
Certain compounds of Table C are the following: Compound B is 6-chloro-4-(S)-cyclopropyl-3,4-dihydro-4-((2- pyridyl)ethynyl)quinazolin-2( 1 H)-one;
Compound C is(-) 6-chloro-4(S)-trifluoromethyl- l ,2-dihydro-4(H)-3, l - benzoxazin-2-one; nevirapine is 1 1 -cyclopropy 1-5, 1 1 -dihydro-4-methy 1- 6 /-dipyrido[3,2- ?:2',3'-<?][ l ,4]diazepin-6-one. Compounds B and C are synthesized by the methods of EP 0,569,083, herein incoφorated by reference for this puφose. Nevirapine is synthesized by Klunder, J. M. et ai, J. Med. Chem. 35, 1887 ( 1992); Hargrave, K. D. et al., J. Med Chem. 34, 2231 ( 1991); Cohen, K. A. et al. '. Biol. Chem. 266, 14670 ( 1991 ), all three references herein incoφorated by reference. Preferred combinations are simultaneous or alternating treatments of an inhibitor of HIV protease and a non-nucleoside inhibitor of HIV reverse transcriptase. An optional third component in the combination is a nucleoside inhibitor of HIV reverse transcriptase, such as AZT, ddC or ddl. A preferred inhibitor of HIV protease is Compound A. Preferred non-nucleoside inhibitors of HIV reverse transcriptase include Compound B, Compound C or nevirapine. These combinations may have synergistic effects on limiting the spread of HIV. Preferred combinations include the following ( 1 ) Compound A, with a preferred non-nucleoside inhibitor of HIV reverse transcriptase, and, optionally, AZT or ddl or ddC; (2) Compound A, and any of AZT or ddl or ddC.
Assay for Inhibition of Microbial Expressed HIV Protease
Inhibition studies of the reaction of the protease expressed in Eschericia coli with a peptide substrate [Val-Ser-Gln-Asn- (betanapthyl)Ala-Pro-Ile-Val, 0.5 mg/mL at the time the reaction is initiated] were in 50 mM Na acetate, pH 5.5, at 30°C for 1 hour. Various concentrations of inhibitor in 1.0 μl DMSO were added to 25 μl of the peptide solution in water. The reaction is initiated by the addition of 15 μl of 0.33 nM protease (0.1 1 ng) in a solution of 0.133 M Na acetate pH 5.5 and 0.1 % bovine serum albumin. The reaction was quenched with 160 μl of 5% phosphoric acid. Products of the reaction were separated by HPLC (VYDAC wide pore 5 cm C- 18 reverse phase, acetonitrile gradient, 0.1 % phosphoric acid). The extent of inhibition of the reaction was determined as IC50 from the peak heights of the products. HPLC of the products, independently synthesized, proved quantitation standards and confirmation of the product composition.
CELL SPREAD ASSAY
Inhibition of the spread of HIV in cell culture was measured according to Nunberg, J. H. et al., J. Virol. 65, 4887 (1991 ). In this assay, MT-4 T-lymphoid cells were infected with HIV- 1 (wild- type, unless otherwise indicated) by using a predetermined inoculum, and cultures were incubated for 24 h. At this time, <1 % of the cells were positive by indirect immunofluorescence. Cells were then extensively washed and distributed into 96-well culture dishes. Serial twofold dilutions of inhibitor were added to the wells, and cultures were continued for 3 additional days. At 4 days postinfection, 100% of the cells in control cultures were infected. HIV-1 p24 accumulation was directly correlated with virus spread. The cell culture inhibitory concentration was defined as the inhibitor concentration in nanomoles/liter which reduced the spread of infection by at least 95%, or CIC95-
INHIBITION OF VIRUS SPREAD
A. Preparation of HIV-infected MT-4 cell Suspension. MT cells were infected at Day 0 at a concentration of 250,000 per ml with a 1 : 1000 dilution of HIV-1 strain Illb stock (final 125 pg p24/ml; sufficient to yield <1 % infected cells on day 1 and 25- 100% on day 4). Cells were infected and grown in the following medium: RPMI 1640 (Whittaker BioProducts), 10% inactivated fetal bovine serum, 4 mM glutamine (Gibco Labs) and 1 : 100 Penicillin- Streptomycin (Gibco Labs).
The mixture was incubated overnight at 37°C in 5% C02 atmosphere.
B. Treatment with Inhibitors A matrix of nanomolar range concentrations of the pairwise combinations is prepared. At Day 1 , aliquots of 125 μl of inhibitors are added to equal volumes of HIV-infected MT-4 cells (50,000 per well) in a 96-well microtiter cell culture plate. Incubation is continued for 3 days at 37°C in 5% CO2 atmosphere.
C. Measurement of Virus Spread
Using a multichannel pipettor, the settled cells are resuspended and 125 μl harvested into a separate microtiter plate. The supernatant is assayed for HIV p24 antigen. The concentration of HIV p24 antigen is measured by an enzyme immunoassay, described as follows. Aliquots of p24 antigen to be measured are added to microwells coated with a monoclonal antibody specific for HIV core antigen. The microwells are washed at this point, and at other appropriate steps that follow. Biotinylated HIV-specific antibody is then added, followed by conjugated streptavidin- horseradish peroxidase. A color reaction occurs from the added hydrogen peroxide and tetramethylbenzidine substrate. Color intensity is proportional to the concentration of HIV p24 antigen.
Calculation of Degree of Synergy or Enhanced Inhibition
When there is synergy pairwise combinations of inhibitors are found to exhibit markedly enhanced inhibition of virus spread, in comparison to each inhibitor alone, or in comparison to merely additive inhibition of each inhibitor.
The data is processed as follows: fractional inhibitory concentration ratios (FIC) are calculated according to Elion, et ai, J. Biol. Chem., 208, All ( 1954). The minimum sum of FICS, which is the maximum synergy, is determined for various pairwise combinations. The smaller the number, the greater the synergy.
EXAMPLE 1
A. Culture Preparation Culture MA7065 was grown in seed and biotransformation media, respectively. Seed medium (KE medium) consisted of: 0.1 % dextrose; 1 % dextrin; 0.3% beef extract; 0.5% ardamine pH; 0.5% NZ amine type E; 0.005% MgSθ4«7H2θ, and 0.037% K2HPO4 with pH adjusted to 7.1 with 0.05% CaC03. Biotransformation medium (soy- glucose) contained: 2% glucose; 0.5% soya meal; 0.5% yeast extract; 0.5% NaCl: 0.98% MES with pH adjusted to 7.0. B. Biotransformation Screening
MA7065 was grown in KE seed medium. After overnight incubation at 27°C with gyratory shake (220 φm) two milliliters of each culture was transferred into 250 ml baffled flasks containing 50 ml of soy-glucose bioconversion medium. At zero time, 5 mg of
Compound J, dissolved in 0.5 ml DMSO, was added to each flask and incubation continued as for seed culture. At various time intervals, a sample of the biotransformation culture was examined by HPLC. At the time of maximal conversion of the substrate, as determined by HPLC, the cultures were harvested and subjected to isolation, purification and characterization.
C. Isolation and Characterization of the Biotransformation Products The content of ten flasks initially containing 25 mg of the
HIV-protease inhibitor, Compound J, were pooled and centrifuged. The supernatant was recovered and applied on the top of an activated column containing 14% octadecyl support. The column was washed with water and then eluted with a gradient of an aqueous methanol from 20 to 80%. Each eluted fraction was examined by HPLC on an analytical column. This column was developed with a gradient solvent system consisting of reservoir A and B. Reservoir A contained 10% ammonium acetate : 0.1 % formic acid and reservoir B contained 67% acetonitrile : 33% methanol : 0.1 % formic acid. The gradient was run from 30 to 85% solvent B in 30 min. Based on the result from the analytical column, fractions containing desired metabolites were eluted with 60 to 80% aqueous methanol from the activated column. This fraction was therefore further purified on a semi-prep. Four resolved fractions from the analytical column was each isolated and after further purification were submitted for NMR, FAB-MS analysis and biological evaluation. EXAMPLE 2
Four samples isolated from an incubation of the HIV protein inhibitor Compound J with bacterial culture MA7065 were characterized by mass spectral analysis. As shown below, Compounds A, Cl , C2, D and E were characterized. Oxidation of the indanyl, phenyl, and pyridine rings was observed.
Mass spectra and daughter ion spectra were obtained by LC/MS/MS on a mass spectrometer using the ionspray interface. Samples were analyzed by direct injection in a mobile phase that consisted of 50% CH3CN/50% 10 mM NH4θAc/0.1 % TFA. Positive ion detection was used.
Figure imgf000031_0001
Compound J
The mass spectrum of J gave an (M+H)+ = 614, which indicated a molecular weight of 613 Da. Four key fragment ions in the daughter ion spectrum of J at m/z 513, 465, 421 , and 338, made it possible to determine the general site of metabolism for these samples. The following table summarizes the results of the analysis of these spectra and includes samples of MA7065 biotransformation products (68051 -A, 68051 -9C, 68051 -12 Fl and 68051 -12 F3) as well as products from other microorganisms. TABLE
Sample Compound Mol. Weight Addition of: Site of Addition
68051 -5 X 1 645 two hydroxyls phenyl, indanyl
68051 -5 X2 629 hydroxyl indanyl
68051 -5 X3 627 ketone indanyl
68051 -9 A* (E) 629 oxygen pyridine
+ 629 hydroxyl indanyl
68051 -9 B 629 hydroxyl indanyl
68051 -9 C 629 hydroxyl indanyl
68051 -12 Fl (Cl & C2) 629 hydroxyl indane
68051 - 12 F2 (D) 629 hydroxyl phenyl
68051 - 12 F3 (E) 629 oxygen pyridine A hydroxyl indanyl
* Sample was determined to be a mixture of two oxygenated compounds
The structures of these compounds were conformed by NMR spectroscopic analysis.
EXAMPLE 3
HIV Protease Inhibitory Activity of Compound J Bioconversion
Products
Seven Compound J bioconversion products were assayed for in vitro HIV protease inhibitory by the assay for inhibition of microbial expressed HIV Protease, protocol given above. Four of the bioconversion products were isolated from MA7065 incubations, Compounds A, Cl , C2. D and E. The IC50 of the parent Compound J was divided by the IC50 of each test compound and multiplied by 100 in order to calculate the percent potency of each compound relative to J.
In some cases, the dilution of the test compound was based on nominal weight. In other cases, especially when the weight was less than 250 μg, the concentration was checked by HPLC using J as standard.
% Potency Relative to Compound J
Based On Compound Wt. Ree d Nominal Wt. Based on HPLC
A 750 μg 27% -—a
(2,3-Trans-OH)
B 240 μg -—a 1 15%
(2,3-Cis-OH)
C 50 μg 8.6% 86%
(5- or 6-OH-Indane)
D 50 μg 3.1 % 31 %
(p-OH-Phenyl)
E 250 μg 34% —-a
(N-Oxide)
F 1000 μg 16% -—a
(3-Ketone)
aNot calculated EXAMPLE 4
Preparation of Amide 1
Figure imgf000034_0001
A solution of (-)-cis- l -aminoindan-2-ol (884 g, 5.93 mol) in 17.8 L of dry THF (KF = 55 mg/mL) (KF stands for Karl Fisher titration for water) and triethylamine (868 mL, 6.22 mol) in a 50 L round bottom flask equipped with a thermocouple probe, mechanical stirrer, and a nitrogen inlet adapter and bubbler, was cooled to 15°C. Then. 3-phenylpropionyl chloride ( 1000 g, 5.93 mol) was added over 75 minutes, while the internal temperature was kept between 14-24°C with an ice-water cooling batch. After addition, the mixture was aged at 18 to 20°C for 30 minutes and checked by HPLC analysis for the disappearance of (-)-cis- l -aminoindan-2-ol.
Progress of the reaction is monitored by high performance liquid chromatography (HPLC) analysis: 25 cm Dupont C8-RX column, 60:40 acetonitrile/10 mM (KH2PO4/K2HPO4), 1.0 mL/min, injection volume = 20 mL, detection = 200 nm, sample preparation = 500 X dilution. Approximate retention times:
retention time (min) identity 6.3 cis-aminoindanol
The reaction was treated with pyridinium -toluene- sulfonate (241 g, 0.96 mol, 0.16 equiv.) and stirred for 10 minutes (the pH of the mixture after diluting 1 mL sample with an equal volume of water is between 4.3-4.6). Then, 2-methoxypropene ( 1.27 L, 13.24 mol, 2.2 equiv.) was added and reaction was heated to 38-40°C for 2 h. The reaction mixture was cooled to 20°C and partitioned with ethyl acetate ( 12 L) and 5% aqueous NaHCθ3 (10 L). The mixture was agitated and the layers were separated. The ethyl acetate extract was washed with 5% aqueous NaHC03 (10 L) and water (4 L). The ethyl acetate extract was dried by atmospheric distillation and solvent switched to cyclohexane (total volume of ~30L). At the end of the distillation and concentration (20 volume % of ethyl acetate extraction volume), the hot cyclohexane solution was allowed to slowly cool to 25°C to crystallize the product. The resulting slurry was further cooled to 10°C and aged for 1 h. The product was isolated by filtration and the wet cake was washed with cold ( 10°C) cyclohexane (2 X 800 mL). The washed cake was dried under vacuum (26" of Hg) at 40°C to afford 1.65 kg of acetonide 1 (86.4%, 98 area% by HPLC), lH NMR (300.13 MHz, CDC13, major rotamer) δ 7.36-7.14 (m, 9 H), 5.03 (d, J=4.4, 1 H), 4.66 (m, 1 H) 3.15 (m, 2 H), 3.06 (br s, 2 H), 2.97 (m, 2 H), 1.62 (s, 3 H), 1.37 (s, 3 H); 13c NMR (75.5 MHz, CDCI3. major rotamer) δc 168.8, 140.9, 140.8, 140.6, 128.6, 128.5, 128.4, 127.1 , 126.3, 125.8, 124.1, 96.5, 78.6, 65.9, 38.4, 36.2, 31.9, 26.5, 24.1. Anal. Calcd for C21 H23N02: C, 78.47; H. 7.21 ; N, 4.36. Found: C, 78.65; H, 7.24; N, 4.40.
EXAMPLE 5
Preparation of Epoxide 3
Figure imgf000035_0001
A solution of acetonide 1 ( 1000 g, 3.1 1 mol) and 2(S)- glycidyl tosylate 2 (853 g, 3.74 mol, 1.2 equiv.) in 15.6 L of THF (KF = 22 mg/mL) in a 50 L 4-neck round bottom flask, equipped with a thermocouple, mechanical stirrer, addition funnel and nitrogen inlet adapter was degassed 3 times via vacuum-nitrogen purge and cooled to -56°C. Then, lithium hexamethyldisilazide (LiN[(CH3)3Si]2)(2.6 L, 1.38 M, 1.15 equiv.) was added over 2 h, while keeping the internal temperature between -50 to -45 °C. The reaction mixture was stirred at -45 to -40°C for 1 h and then allowed to warm to -25°C over 1 h. The mixture is stirred between -25 to -22°C for 4 h (or until the starting acetonide is 3.0 area %).
Progress of the reaction is monitored by HPLC analysis: 25 cm X 4.6 nm Zorbax Silica column, 20% ethyl acetate in hexane, 2.0 mL/min, injection volume = 20 mL, detection = 254 nm, sample preparation = 100 X dilution. Approximate retention times:
retention time (min). identity
5.5 amide 1
6.5 glycidyl tosylate 2
13.5 epoxide 3
The reaction mixture was quenched with DI water (6.7 L) at -15°C and partitioned with ethyl acetate ( 10 L). The mixture was agitated and the layers were separated. The ethyl acetate extract was washed with a mixture of 1 % aqueous NaHCθ3 (5 L) and saturated NaCl (0.5 L). The ethyl acetate extract (28.3 L) was concentrated by vacuum distillation (28" of Hg) and additional ethyl acetate was added to complete the solvent switch to ethyl acetate (final volume = 1 1.7 L). The ethyl acetate concentrate was further solvent switched to MeOH to crystallize the product and concentrated to a final volume of 3.2 L. The residual ethyl acetate solvent was removed by charging 10 L of methanol and collecting 10 L of distillate. The resulting slurry was stirred at 22°C for 1 h, then cooled to 5°C and aged for 0.5 h. The product was isolated by filtration and the wet cake was washed with cold methanol (2 X 250 mL). The washed cake was dried under vacuum (26" of Hg) at 25°C to afford 727 g of epoxide 3 (61.2%, 98.7 area % of the major epoxide by HPLC): 13c NMR (75.5 MHz, CDC13) δ
171.1 , 140.6, 140.5, 139.6, 129.6, 128.8, 128.2, 127.2, 126.8, 125.6, 124.1 , 96.8, 79.2, 65.8, 50.0, 48.0, 44.8, 39.2, 37.4, 36.2, 26.6, 24.1.
EXAMPLE 6
Preparation of penultimate 6
Figure imgf000037_0001
Figure imgf000038_0001
A slurry of the 2(S)-t-butylcarboxamide-4-/V-Boc- piperazine 4 ( 1950 g, 6.83 mol, >99.5% ee) (ee = enantiomeric excess) and the epoxide 3 (2456 g, 97.5:2.5 mixture of ASIR epoxides, 6.51 mol) in isopropanol (2-propanol, 18.6 L) in a 72 L round bottom flask with four inlets, equipped with a mechanical stirrer, reflux condenser, steam bath, Teflon coated thermocouple and nitrogen inlet, was heated to reflux (internal temperature was 84-85°C). After 40 min, a homogeneous solution was obtained. The mixture was heated at reflux for 28 h.
The internal temperature during reflux was 84-85°C. Progress of the reaction was monitored by HPLC analysis: 25 cm Dupont C8-RX column, 60:40 acetonitrile/10 mM (KH2PO4/K2HPO4),
1.0 mL/min, detection = 220 nm, sample preparation = 2 μL, reaction mixture diluted to 1 mL in acetonitrile. Approximate retention times:
retention time (min) identity
4.8 piperazine 4
8.9 epoxide 3
15.2 coupled product 5
After 28 h, the remaining epoxide 3 and coupled product 5 (by HPLC analysis) were 1.5 area % and 91 -93 area %, respectively. The mixture was cooled to 0 to 5°C and 20.9 L of 6 N HC1 was added while keeping the temperature below 15°C. After the addition was complete, the mixture was warmed to 22°C. Evolution of gas is noted at this point (isobutylene). The mixture was aged at 20 to 22°C for 6 h. Progress of the reaction was monitored by HPLC analysis: same conditions as above. Approximate retention times:
retention time (min) identity
7.0 cis-aminoindanol
1 1.9 penultimate 6
15.1 coupled product 5
The mixture was cooled to 0°C and 7.5 L of 50% NaOH was slowly added to adjust the pH of the mixture to pH=l 1.6, while keeping the temperature less than 25°C during the addition. The mixture was partitioned with ethyl acetate (40 L) and water (3 L). The mixture was agitated and the layers were separated. The organic phase (60 L) was concentrated under reduced pressure (29" of Hg) and solvent switched to DMF and concentrated to a final volume of 10.5 L (KF = 1.8 mg/mL). The HPLC assay yield of 6 in ethyl acetate was 86.5%. The penultimate compound 6 in DMF was directly used in the next step without further purification. For isolated 6: 13C NMR (75.4 MHz, CDCl3) δ 175.2, 170.5, 140.8, 140.5, 139.9, 129.1 , 128.5, 127.9, 126.8, 126.5, 125.2, 124.2, 73.0, 66.0, 64.8, 62.2, 57.5, 49.5, 47.9, 46.4, 45.3, 39.6, 39.3, 38.2, 28.9. To 10.0 g (0.019 mol) of N-(2(R)-hydroxy-l (S)-indanyl)-
2(R)-phenylmethyl-4(S)-hydroxy)-5-(l(-2(S)-N-(t-butylcarbamoyl)- piperaziny -pentaneamide 6 and 3.45 g (0.021 mol) of 3-picolyl chloride dissolved in 40 mL of DMF was added 5.85 mL (0.042 mol) of triethylamine. After 3 hours an additional 0.313 g of 3-picolyl chloride was added. After an additional 2 hours the reaction was diluted with 400 mL of EtOAc and washed with water (3 x 75 mL), brine (1 x 100 mL), dried over MgSθ4 and concentrated. The residue was triturated with 30 mL of EtOAc and the resulting white precipitate was collected. Further recrystallization from EtOAc provided the product Compound J (m.p. 167.5-168°C). EXAMPLE 7
Pyrazine-2-tert-butyl carboxamide 9
CONHt-Bu
Figure imgf000040_0001
2-Pyrazinecarboxylic acid (8) 3.35 kg (27 mol)
Oxalyl chloride 3.46 kg (27.2 mol) tert-Butylamine (KF = 460 μg ml) 9.36 L (89 mol)
EtOAc (KF = 56 μg/ml) 27 L
DMF 120 mL
1 -Propanol 30 L
The carboxylic acid 8 was suspended in 27 L of EtOAc and 120 mL of DMF in a 72 L 3-neck flask with mechanical stirring under N2 and the suspension was cooled to 2°C. The oxalyl chloride was added, maintaining the temperature between 5 and 8°C.
The addition was completed in 5 h. During the exothermic addition CO and C02 were evolved. The HC1 that was formed remained largely in solution. A precipitate was present which is probably the HCL salt of the pyrazine acid chloride. Assay of the acid chloride formation was carried out by quenching an anhydrous sample of the reaction with t-butylamine. At completion <0.7% of acid 8 remained.
The assay for completion of the acid chloride formation is important because incomplete reaction leads to formation of a bis-tert- butyl oxamide impurity.
The reaction can be monitored by HPLC: 25 cm Dupont Zorbax RXC8 column with 1 mL/min flow and detection at 250 nm; linear gradient from 98% of 0.1 % aqueous H3PO4 and 2% CH3CN to 50% aqueous H3PO4 and 50% CH3CN at 30 min. Retention times: acid 8 = 10.7 min, amide 9 = 28.1 min.
The reaction mixture was aged at 5°C for 1 h. The resulting slurry was cooled to 0°C and the tert-butylamine was added at such a rate as to keep the internal temperature below 20°C.
The addition required 6 h, as the reaction was very exothermic. A small portion of the generated tert-butylammonium hydrochloride was swept out of the reaction as a fluffy white solid.
The mixture was aged at 18°C for an additional 30 min. The precipitated ammonium salts were removed by filtration. The filter cake was washed with 12 L of EtOAc. The combined organic phases were washed with 6 L of a 3% NaHCθ3 and 2 X 2 L of saturated aq. NaCl. The organic phase was treated with 200 g of Darco G60 carbon and filtered through Solka Flok and the cake was washed with 4 L of EtOAc.
Carbon treatment efficiently removed some puφle color in the product.
The EtOAc solution of 9 was concentrated at 10 mbar to 25% of the original volume. 30 L of 1-propanol were added, and the distillation was continued until a final volume of 20 L was reached.
At this point, the EtOAc was below the limit of detection in the lH NMR (<1 %). The internal temperature in this solvent change was < 30°C. A 1 -propanol/EtO AC solution of 3 was stable to reflux atatmospheric pressure for several days. Evaporation of an aliquot gave a tan solid m.p. 87-88°C. 13c NMR (75 MHz, CDCI3, ppm) 161.8, 146.8, 145.0, 143.8, 142.1 , 51.0, 28.5. EXAMPLE 8
rac-2-tert-Buty 1-carboxamide-piperazine 10
Figure imgf000042_0001
Materials
Pyrazine-2-tert-butylcarboxamide 9 2.4 kg (13.4 mol) in 1 - Propanol solution 12 L 20% Pd(OH)2/C 16 wt.% water 144 g.
The pyrazine-2-tert-butylcarboxamide 9/1 -propanol solution was placed into the 5 gal autoclave. The catalyst was added and the mixture was hydrogenated at 65°C at 40 psi (3 arm) of H2.
After 24 h the reaction had taken up the theoretical amount of hydrogen and GC indicated <1 % of 9. The mixture was cooled, purged with N2 and the catalyst was removed by filtration through Solka Floe. The catalyst was washed with 2 L of warm 1 -propanol. It was found that the use of warm 1 -propanol during washing of the filter cake improved filtration and lowered the losses of product on the filter cake.
The reaction was monitored by GC: 30 m Megabore column, from 100°C to 160°C at 10°C/min, hold 5 min, then at
10°C/min to 250°C, retention times: 9 = 7.0 min, 10 = 9.4 min. The reaction could also be monitored by TLC with EtOAc/MeOH (50:50) as solvent and Ninhydrin as developing agent.
Evaporation of an aliquot indicated that the yield over amidation and hydrogenation is 88% and that the concentration of 10 is 133g/L.
Evaporation of an aliquot gave 10 as a white solid m.p. 150- 151 °C; 13C NMR (75 MHz, D2θ, ppm) 173.5, 59.8, 52.0. 48.7, 45.0, 44.8, 28.7. EXAMPLE 9
(S)-2-tert-Butyl-carboxamide-piperazine bis (S)-Camphorsulfonic acid salt (S -11
Figure imgf000043_0001
10 11
Materials rac-2-tert-Butyl-carboxamide-piperazine 10 4.10 kg (22.12 mol) in 1 -Propanol Solution in 25.5 Kg solvent
(S)-(+)-10-Camphorsulfonic acid 10.0 Kg (43.2 mol) 1 -Propanol 12 L
Acetonitrile 39 L
Water 2.4 L
The solution of amine 10 in 1 -propanol was charged to a 100 L flask with an attached batch concentrator. The solution was concentrated at 10 mbar and a temperature < 25°C to a volume of ca 12
L.
At this point the product had precipitated from the solution, but went back into a solution when the mixture was heated to 50°C. Analysis of a homogeneous aliquot indicated that the concentration of 10 was 341 g/L. The concentration was determined by
HPLC: 25 cm Dupont Zorbax RXC8 column with 1.5 mL/min flow and detection at 210 nm, isocratic (98/2) CH3CN/O.I % aqueous H3PO4.
Retention time of 10 : 2.5 min. Acetonitrile (39 L) and water (2.4 L) were added to give a clear, slightly brown solution.
Determination of the water content by KF titration and
CH3CN/I -propanol ratio by lH NMR integration showed that the CH3CN/l -propanol/H2θ ratio was 26/8/1.6. The concentration in the solution was 72.2 g/ L.
The (S)-lO-camphorsu.fonic acid was charged over 30 min in 4 portions at 20°C. The temperature rose to 40°C after the CSA was added. After a few minutes a thick white precipitate formed. The white slurry was heated to 76°C to dissolve all the solids, the slightly brown solution was then allowed to cool to 21 °C over 8 h.
The product precipitated at 62°C. The product was filtered without aging at 21 °C, and the filter cake was washed with 5 L of the CH3CN / 1 -propanol / H2O 26/8/1.6 solvent mixture. It was dried at 35°C in the vacuum oven with N2 bleed to give 5.6 Kg (39%) of 11 as a white crystalline solid m.p. 288-290°C (with decomp.) lαjD25 = 1 .9° (c = 0.37, H2θ). 13C NMR (75 MHz, D2O, ppm) 222.0, 164.0, 59.3, 54.9, 53.3, 49.0, 48.1 , 43.6, 43.5, 43.1 , 40.6, 40.4, 28.5, 27.2, 25.4, 19.9, 19.8.
The ee of the material was 95% according to the following chiral HPLC assay: an aliquot of 11 (33 mg) was suspended in 4 mL of EtOH and 1 mL of Et3N. Boc2θ ( 1 1 mg) was added and the reaction mixture was allowed to age for 1 h. The solvent was completely removed in vacua, and the residue was dissolved in ca. 1 mL of EtOAc and filtered through a Pasteur pipet with Siθ2, using EtOAc as eluent. The evaporated product fractions were redissolved in hexanes at ca. 1 mg/mL. The enantiomers were separated on a Daicel Chiracell AS column with a hexane/IPA (97:3) solvent system at a flow rate of 1 mL/min and detection at 228 nm. Retention times: S antipode = 7.4 min, R = 9.7 min. EXAMPLE 10
(S)-2-tert-Butylcarboxamide-4-tert-butoxycarbonyl-piperazine 4 from salt 1 1
CONHt-Bu
Figure imgf000045_0001
11 4
Materials
(S)-2-tert-Butyl-carboxamide-piperazine
Bis (S) - (+) - CSA salt 11, 95% ee 5.54 Kg (8.53 mol)
Di-tert-butyl dicarbonate 1.86 Kg (8.53 mol)
Et3N 5.95L (42.6 mol)
EtOH Punctilious 200 proof 55 L
EtOAc 2 L
To the (S)-CSA salt 11 in a 100 L 3-neck flask with an addition funnel under N2 was added EtOH, followed by triethylamine at 25°C. The solid dissolved readily on the addition of the Et3N. The Boc2θ was dissolved in EtOAc and charged to the addition funnel. The solution of Boc2θ in EtOAc was added at such a rate as to keep the temperature below 25°C. The addition took 3 h. The reaction mixture was aged for 1 h after completion of the addition of the Boc2θ solution. The reaction can be monitored by HPLC: 25 cm Dupont Zorbax RXC8 column with 1 mL/min flow and detection at 228 nm, isocratic (50/50) CH3CN/O.I M KH2PO4 adjusted to pH=6.8 with NaOH. Retention time of 4 = 7.2 min. The chiral assay was carried out using the same system as in the previous step. The reaction could also be monitored by TLC with a 100% EtOAc as the solvent. (Rf=0.7)
The solution was then concentrated to ca. 10 L at an internal temperature of <20°C in a batch-type concentrator under 10 mbar vacuum. The solvent switch was completed by slowly bleeding in 20 L of EtOAc and reconcentrating to ca 10 L. The reaction mixture was washed into an extractor with 60 L of EtOAc. The organic phase was washed with 16 L of 5% aqueous Na2Cθ3 solution, 2 X 10 L Di water and 2 X 6 L of saturated aqueous sodium chloride. The combined aqueous washes were back extracted with 20 L of EtOAc and the organic phase was washed with 2 X 3 L water and 2 X 4 L of saturated aqueous sodium chloride. The combined EtOAc extracts were concentrated under 10 mbar vacuum with an internal temperature of <20°C in a 100 L batch-type concentrator to ca. 8 L. The solvent switch to cyclohexane was achieved by slowly bleeding in ca. 20 L of cyclohexane, and reconcentrating to ca. 8 L. To the slurry was added 5 L of cyclohexane and 280 mL of EtOAc and the mixture was heated to reflux, when everything went into solution. The solution was cooled and seed ( 10 g) was added at 58°C. The slurry was cooled to 22°C in 4 h and the product was isolated by filtration after a 1 h age at 22°C. The filter cake was washed with 1.8 L of cyclohexane and dried' in the vacuum oven at 35°C under N2 bleed to give 1.87 Kg (77%, >99.9 area % by HPLC, R-isomer below level of detection) of 4 as a slightly tan powder. lαlD25 = 22.0° (c = 0.20, MeOH), m.p. 107°C; Be NMR (75 MHz, CDC13, ppm) 170.1 , 154.5, 79.8, 58.7, 50.6, 46.6, 43.6, 43.4, 28.6, 28.3.
While the foregoing specification teaches the principles of the present invention, with examples provided for the puφose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations, or modifications, as come within the scope of the following claims and its equivalents.

Claims

WHAT IS CLAIMED IS:
1. A method of synthesizing biotransformation products of the Compound J having the structure:
Figure imgf000047_0001
or salt or hydrate thereof, comprising the steps of
(a) providing a culture of MA7065;
(b) incubating said culture with Compound J;
(c) isolating biotransformation products comprising:
Figure imgf000047_0002
Figure imgf000048_0001
Figure imgf000048_0002
or
Figure imgf000048_0003
Figure imgf000049_0001
or salt or hydrate thereof.
2. A purified biotransformation product of the method of Claim 1.
3. The compound, which is
Figure imgf000049_0002
Figure imgf000049_0003
Figure imgf000050_0001
Figure imgf000050_0002
or salt or hydrate thereof.
4. A pharmaceutical composition comprising the compound of Claim 3. and a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of Claim 3, for use in the treatment of and the delaying of the onset of AIDS, in the prevention of infection of HIV, in the treatment of infection of HIV, or in the inhibition of HIV protease.
6. A method of treating and delaying the onset of AIDS, comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 3.
7. A method of preventing infection by HIV comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 3.
8. A method of treating infection by HIV, comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 3.
9. A method of inhibiting HIV protease, comprising administering to a mammal in need of such treatment an effective amount of a compound of Claim 3.
10. A combination of compounds, which is a compound of Claim 3, and any of AZT or ddl or ddC.
1 1. A pure culture of MA7065.
PCT/US1995/013628 1994-10-25 1995-10-20 Microbial synthesis of hiv protease inhibitors WO1996012492A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA 2203272 CA2203272A1 (en) 1994-10-25 1995-10-20 Microbial synthesis of hiv protease inhibitors
EP95937602A EP0785786A4 (en) 1994-10-25 1995-10-20 Microbial synthesis of hiv protease inhibitors
AU39663/95A AU702122B2 (en) 1994-10-25 1995-10-20 Microbial synthesis of HIV protease inhibitors
JP8514082A JPH10507917A (en) 1994-10-25 1995-10-20 Microbial synthesis of HIV protease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32863494A 1994-10-25 1994-10-25
US328,634 1994-10-25

Publications (1)

Publication Number Publication Date
WO1996012492A1 true WO1996012492A1 (en) 1996-05-02

Family

ID=23281761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/013628 WO1996012492A1 (en) 1994-10-25 1995-10-20 Microbial synthesis of hiv protease inhibitors

Country Status (4)

Country Link
EP (1) EP0785786A4 (en)
JP (1) JPH10507917A (en)
AU (1) AU702122B2 (en)
WO (1) WO1996012492A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0785989A1 (en) * 1994-10-25 1997-07-30 Merck & Co., Inc. Microbial synthesis of hiv protease inhibitors
US5763196A (en) * 1996-01-26 1998-06-09 Boehringer Mannheim Corporation Assays using cross-linked polypeptide fragments of β-galactosidase
US5976857A (en) * 1996-01-26 1999-11-02 Boehringer Mannheim Corporation Cross-linked polypeptide fragments of β-galactosidase
US5976783A (en) * 1996-01-26 1999-11-02 Boehringer Mannheim Corporation Bis-maleimido cross-linking agents
JP2004115510A (en) * 2002-09-05 2004-04-15 Toray Fine Chemicals Co Ltd Method for producing piperazine derivative
CN100360510C (en) * 2002-09-05 2008-01-09 东丽泛应化学(股) Process for producing oxycarbonyl-substituted piperazine derivative
CN101497608B (en) * 2009-03-05 2011-11-09 中国科学院广州生物医药与健康研究院 HIV protease inhibitor derivative, preparation thereof and use in antineoplastic medicament preparation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3160560A (en) * 1957-08-23 1964-12-08 Upjohn Co Streptolydigin and production thereof
US4497797A (en) * 1980-10-27 1985-02-05 Shionogi & Co., Ltd. β-Galactosidase inhibitor GT-2558 and its derivatives
EP0541168A1 (en) * 1991-11-08 1993-05-12 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
CA2110827A1 (en) * 1992-12-14 1994-06-15 Maki Nishio Antiviral antibiotic bu-4724v and preparation thereof
EP0617968A1 (en) * 1993-03-31 1994-10-05 Merck & Co. Inc. HIV protease inhibitors in pharmaceutical combinant for the treatment of AIDS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612217A (en) * 1994-10-25 1997-03-18 Merck & Co., Inc. Streptomyces sp. MA 7074 (ATCC 55605) used for microbial synthesis of HIV protease inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3160560A (en) * 1957-08-23 1964-12-08 Upjohn Co Streptolydigin and production thereof
US4497797A (en) * 1980-10-27 1985-02-05 Shionogi & Co., Ltd. β-Galactosidase inhibitor GT-2558 and its derivatives
EP0541168A1 (en) * 1991-11-08 1993-05-12 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
CA2110827A1 (en) * 1992-12-14 1994-06-15 Maki Nishio Antiviral antibiotic bu-4724v and preparation thereof
EP0617968A1 (en) * 1993-03-31 1994-10-05 Merck & Co. Inc. HIV protease inhibitors in pharmaceutical combinant for the treatment of AIDS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. LASKIN et al., CRC Handbook of Microbiology, Published 1977, by CRC PRESS INC. (FLORIDA), pages 551 and 554. *
PROC. NATL. ACAD. SCI. U.S.A., Volume 91, issued April 1994, J.P. VACCA et al., "L-735,524: An Orally Bioavailable Human Immunodeficiency Virus Type 1 Protease Inhibitor", pages 4096-4100. *
See also references of EP0785786A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0785989A1 (en) * 1994-10-25 1997-07-30 Merck & Co., Inc. Microbial synthesis of hiv protease inhibitors
EP0785989A4 (en) * 1994-10-25 1998-01-28 Merck & Co Inc Microbial synthesis of hiv protease inhibitors
US5763196A (en) * 1996-01-26 1998-06-09 Boehringer Mannheim Corporation Assays using cross-linked polypeptide fragments of β-galactosidase
US5976857A (en) * 1996-01-26 1999-11-02 Boehringer Mannheim Corporation Cross-linked polypeptide fragments of β-galactosidase
US5976783A (en) * 1996-01-26 1999-11-02 Boehringer Mannheim Corporation Bis-maleimido cross-linking agents
JP2004115510A (en) * 2002-09-05 2004-04-15 Toray Fine Chemicals Co Ltd Method for producing piperazine derivative
CN100360510C (en) * 2002-09-05 2008-01-09 东丽泛应化学(股) Process for producing oxycarbonyl-substituted piperazine derivative
US7569690B2 (en) * 2002-09-05 2009-08-04 Toray Fine Chemicals Co., Ltd. Process for producing oxycarbonyl-substituted piperazine derivative
CN101497608B (en) * 2009-03-05 2011-11-09 中国科学院广州生物医药与健康研究院 HIV protease inhibitor derivative, preparation thereof and use in antineoplastic medicament preparation

Also Published As

Publication number Publication date
AU3966395A (en) 1996-05-15
EP0785786A1 (en) 1997-07-30
JPH10507917A (en) 1998-08-04
EP0785786A4 (en) 1998-01-28
AU702122B2 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
IE913647A1 (en) Hydroxylated inhibitors of hiv reverse transcriptase
US5646148A (en) HIV protease inhibitors useful for the treatment of AIDS
EP0696277A1 (en) Hiv protease inhibitors useful for the treatment of aids
KR20050098928A (en) Substituted heterocycles
AU702122B2 (en) Microbial synthesis of HIV protease inhibitors
US6395743B1 (en) HIV integrase inhibitors
US5612217A (en) Streptomyces sp. MA 7074 (ATCC 55605) used for microbial synthesis of HIV protease inhibitors
GB2306476A (en) Hiv integrase inhibitors
US5858737A (en) Conversion of indene to (1S)-amino-(2R)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps
WO1997000966A1 (en) Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of dioxygenase bioconversion and chemical steps
KR100453301B1 (en) 1-Trifluoromethyl-4-Hydroxy-7-Piperidinyl-Aminomethylchroman Derivatives
US5605819A (en) Quantitative conversion of indene to (1S,2R) indene oxide and (1S,2R)-indandiol by combination of haloperoxidase bioconversion and chemical steps
CA2203273A1 (en) Microbial synthesis of hiv protease inhibitors
JPH0570448A (en) Hiv protease inhibitor
CA2203272A1 (en) Microbial synthesis of hiv protease inhibitors
US5871981A (en) Conversion of indene to (1S)-amino-(2R)-indanol free of any steroisomer by combination of fermentation of Rhodococcus sp. ATCC 55805 and chemical steps
US6221899B1 (en) Terpenoid lactone compounds and their production process
US6277860B1 (en) Furopyridine antibacterials
US5002959A (en) BU-4146T antibiotic
US5824540A (en) Pseudomonas putida strain with dioxygenase activity
CA2260413C (en) Terpenoid lactone compounds and their production process
WO1998006865A1 (en) Conversion of indene to (1s)-amino-(2r)-indanol free of any stereoisomer, by combination of monooxygenase bioconversion and chemical steps
US5037836A (en) BU-4146T antibiotic
EP0999212A1 (en) Furopyridine antibacterials

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995937602

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2203272

Country of ref document: CA

Ref country code: CA

Ref document number: 2203272

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1995937602

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995937602

Country of ref document: EP